Investigational Drug Information for CUDC-101
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug CUDC-101?
CUDC-101 is an investigational drug.
There have been 12 clinical trials for CUDC-101.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2016.
The most common disease conditions in clinical trials are Lymphoma, Neoplasms, and Head and Neck Neoplasms. The leading clinical trial sponsors are Curis, Inc., National Cancer Institute (NCI), and The Leukemia and Lymphoma Society.
There are two hundred and eighty US patents protecting this investigational drug and two international patents.
Summary for CUDC-101
| US Patents | 280 |
| International Patents | 2,561 |
| US Patent Applications | 991 |
| WIPO Patent Applications | 736 |
| Japanese Patent Applications | 376 |
| Clinical Trial Progress | Phase 2 (2016-01-01) |
| Vendors | 77 |
Recent Clinical Trials for CUDC-101
| Title | Sponsor | Phase |
|---|---|---|
| The Safety and Efficacy of a Novel HSP90 Inhibitor (CUDC-305) in the Treatment of Moderate to Severe Psoriasis. | Aarhus University Hospital | Phase 1 |
| CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer | National Cancer Institute (NCI) | Phase 2 |
| Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies | National Cancer Institute (NCI) | Phase 1/Phase 2 |
Clinical Trial Summary for CUDC-101
Top disease conditions for CUDC-101
Top clinical trial sponsors for CUDC-101
US Patents for CUDC-101
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| CUDC-101 | See Plans and Pricing | Histone deacetylase inhibitors and methods for use thereof | REACTION BIOLOGY CORP. (Malvern, PA) | See Plans and Pricing |
| CUDC-101 | See Plans and Pricing | Anti-CS1 antibodies and antibody drug conjugates | AbbVie Biotherapeutics Inc. (Redwood City, CA) | See Plans and Pricing |
| CUDC-101 | See Plans and Pricing | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III | Frequency Therapeutics, Inc. (Woburn, MA) | See Plans and Pricing |
| CUDC-101 | See Plans and Pricing | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (Atlanta, GA) | See Plans and Pricing |
| CUDC-101 | See Plans and Pricing | Methods and compositions for treating antiprogestin-resistant cancers | FUNDACION SALES (Capital Federal, AR) | See Plans and Pricing |
| CUDC-101 | See Plans and Pricing | 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]- pyrimidin-5 (1h)-one, salts thereof and methods of using the same in combination therapy | Oncoceutics, Inc. (Philadelphia, PA) | See Plans and Pricing |
| CUDC-101 | See Plans and Pricing | Compositions of obeticholic acid and methods of use | Intercept Pharmaceuticals, Inc. (New York, NY) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for CUDC-101
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| CUDC-101 | World Intellectual Property Organization (WIPO) | WO2017030892 | 2035-08-14 | See Plans and Pricing |
| CUDC-101 | Australia | AU2015339012 | 2034-10-31 | See Plans and Pricing |
| CUDC-101 | Brazil | BR112017008945 | 2034-10-31 | See Plans and Pricing |
| CUDC-101 | Canada | CA2966005 | 2034-10-31 | See Plans and Pricing |
| CUDC-101 | European Patent Office | EP3212668 | 2034-10-31 | See Plans and Pricing |
| CUDC-101 | Spain | ES2832711 | 2034-10-31 | See Plans and Pricing |
| CUDC-101 | Japan | JP2017537893 | 2034-10-31 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
